samedan logo
 
 
spacer
home > pmps > summer 2002 > the cphi worldwide 2002 conference preview - where science comes first
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The CPhI Worldwide 2002 Conference Preview - Where Science Comes First

This is where the CPhI conference comes in. The two-day programme will include high profile speakers presenting papers with in-depth scientific information on pharmaceutical techniques. The best way to measure the success of an exhibition such as CPhI Worldwide is to look at the actual number of attendees. Last year's combined event hosted 8,703 individual visitors, from over 110 countries around the world. Together with the exhibitors, the CPhI event in 2001 attracted almost 18,000 industry professionals.




France - A Major Market for Pharmaceuticals

'The French fine pharmaceutical chemicals industry is responsible for an annual turnover of US$3.7 billion and creates employment for over 20,000 people. Its 58 million residents - the second largest market in Europe and fourth largest in the world - are Europe's largest per capita consumers of pharmaceutical products. When calculated as a percentage of total health spending, France spends twice as much as the US does on medicine. Total turnover for pharmaceutical products amounted to US$20 billion in 1996 (approximately US$18 billion), about a quarter of which was exported.

The French pharmaceutical industry comprises 334 pharmaceutical companies in a very fragmented market. The top 20 companies in France controlled just 53 per cent of the domestic market in 1996. France ranked third after the US and Japan in a number of new pharmaceutical product launches in 1995. In 1996, France hosted the second highest number of biotech companies in Europe and, this year, hosts the third highest (1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Rebecca Caval˘t of PMPS
spacer
Rebecca Caval˘t
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera launches UniSpray, its unidose system primarily for systemic-acting drug administration

Nemera has a proven track record in developing and manufacturing complex Ear Nose and Throat solutions. In line with clear growing market interest in unidose system coupled with promising advantages that nasal route could offer, Nemera is thrilled to extend its portfolio by launching its unidose system, UniSpray, for systemic-acting drug administration to face emergency and crisis.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement